128 related articles for article (PubMed ID: 28156154)
1. INSULIN TIMING: A PATIENT-CENTERED APPROACH TO IMPROVE CONTROL IN TYPE 1 DIABETES.
Duran-Valdez E; Burge MR; Broderick P; Shey L; Valentine V; Schrader RM; Schade DS
Endocr Pract; 2017 Apr; 23(4):471-478. PubMed ID: 28156154
[TBL] [Abstract][Full Text] [Related]
2. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
[TBL] [Abstract][Full Text] [Related]
4. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes.
Mulinacci G; Alonso GT; Snell-Bergeon JK; Shah VN
Diabetes Technol Ther; 2019 Jan; 21(1):6-10. PubMed ID: 30575413
[TBL] [Abstract][Full Text] [Related]
5. Insulin Sensitivity Index-Based Optimization of Insulin to Carbohydrate Ratio: In Silico Study Shows Efficacious Protection Against Hypoglycemic Events Caused by Suboptimal Therapy.
Schiavon M; Dalla Man C; Cobelli C
Diabetes Technol Ther; 2018 Feb; 20(2):98-105. PubMed ID: 29355438
[TBL] [Abstract][Full Text] [Related]
6. The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy.
Sahin SB; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C
Acta Diabetol; 2010 Dec; 47(4):325-30. PubMed ID: 20842389
[TBL] [Abstract][Full Text] [Related]
7. Optimization of insulin regimen and glucose outcomes with short-term real-time continuous glucose monitoring (RT-CGM) in type 1 diabetic children with sub-optimal glucose control on multiple daily injections: The pediatric DIACCOR study.
Picard S; Bonnemaison-Gilbert E; Leutenegger E; Barat P
Arch Pediatr; 2019 Feb; 26(2):95-101. PubMed ID: 30642746
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
[TBL] [Abstract][Full Text] [Related]
9. Improved A1C by switching to continuous subcutaneous insulin infusion from injection insulin therapy in type 2 diabetes: A retrospective claims analysis.
Lynch P; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
Prim Care Diabetes; 2010 Dec; 4(4):209-14. PubMed ID: 20832374
[TBL] [Abstract][Full Text] [Related]
10. Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?
Gingras V; Desjardins K; Smaoui MR; Savard V; Messier V; Haidar A; Legault L; Rabasa-Lhoret R
Acta Diabetol; 2018 Mar; 55(3):227-231. PubMed ID: 29224132
[TBL] [Abstract][Full Text] [Related]
11. A1c, glucose variability and hypoglycemia risk in patients with type 1 diabetes.
Guelho D; Paiva I; Batista C; Barros L; Carrilho F
Minerva Endocrinol; 2014 Jun; 39(2):127-33. PubMed ID: 24736487
[TBL] [Abstract][Full Text] [Related]
12. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function.
Sherr J; Tamborlane WV; Xing D; Tsalikian E; Mauras N; Buckingham B; White NH; Arbelaez AM; Beck RW; Kollman C; Ruedy K;
Diabetes Care; 2012 Apr; 35(4):817-20. PubMed ID: 22323414
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes.
Summers JC; Briganti EM; Fitzgerald ZA; Lambers LNJ; Cohen ND
Diabetes Technol Ther; 2019 Aug; 21(8):423-429. PubMed ID: 31180239
[No Abstract] [Full Text] [Related]
14. Switching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptoms.
Nattero-Chávez L; Lecumberri Pascual E; De La Calle E; Bayona Cebada A; Ruiz T; Quintero Tobar A; Lorenzo M; Sánchez C; Izquierdo A; Luque-Ramírez M; Escobar-Morreale HF
Diabetes Res Clin Pract; 2023 May; 199():110627. PubMed ID: 36940793
[TBL] [Abstract][Full Text] [Related]
15. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
Hirsch IB; Abelseth J; Bode BW; Fischer JS; Kaufman FR; Mastrototaro J; Parkin CG; Wolpert HA; Buckingham BA
Diabetes Technol Ther; 2008 Oct; 10(5):377-83. PubMed ID: 18715214
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial.
Jenkins AJ; Krishnamurthy B; Best JD; Cameron FJ; Colman PG; Farish S; Hamblin PS; O'Connell MA; Rodda C; Rowley K; Teede H; O'Neal DN
Diabetes Care; 2010 Jun; 33(6):1242-8. PubMed ID: 20215457
[TBL] [Abstract][Full Text] [Related]
17. Closed-Loop Control of Postprandial Glycemia Using an Insulin-on-Board Limitation Through Continuous Action on Glucose Target.
Rossetti P; Quirós C; Moscardó V; Comas A; Giménez M; Ampudia-Blasco FJ; León F; Montaser E; Conget I; Bondia J; Vehí J
Diabetes Technol Ther; 2017 Jun; 19(6):355-362. PubMed ID: 28459603
[TBL] [Abstract][Full Text] [Related]
18. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring.
Pettus J; Edelman SV
Diabetes Technol Ther; 2016 Feb; 18 Suppl 2(Suppl 2):S234-42. PubMed ID: 26784128
[TBL] [Abstract][Full Text] [Related]
19. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial.
Fanelli CG; Pampanelli S; Porcellati F; Rossetti P; Brunetti P; Bolli GB
Ann Intern Med; 2002 Apr; 136(7):504-14. PubMed ID: 11926785
[TBL] [Abstract][Full Text] [Related]
20. POSTPRANDIAL DOSING OF BOLUS INSULIN IN PATIENTS WITH TYPE 1 DIABETES: A CROSS-SECTIONAL STUDY USING DATA FROM THE T1D EXCHANGE REGISTRY.
Peters A; Van Name MA; Thorsted BL; Piltoft JS; Tamborlane WV
Endocr Pract; 2017 Oct; 23(10):1201-1209. PubMed ID: 28704103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
